Coming soon! Update from ESC 2026: Treatment and prevention of acute coronary syndrome (ACS)

Gilles Montalescot is Professor of Cardiology at the Pitié Salpêtrière Hospital in Paris, France, where he heads the Department of Cardiology at the Institute of Cardiology. He is a practicing Interventional Cardiologist and has extensive experience in basic and clinical research. He has been the director of the INSERM research Unit UMRS_1166 on Thrombosis for 10 years.

Dr Montalescot has been an investigator for many of the new drugs developed in the past twenty years as well as for many of the new interventional technologies. Dr Montalescot is a senior scientist and has been the lead investigator of many national or international randomized trials including ADMIRAL, ARMADA, ALBION, STEEPLE, ARCHIPELAGO, ABOARD, ACAPULCO, ATOLL, ARCTIC, ANTARCTIC, ACCOAST, ATLANTIC, AEGEAN, AMERICA, ALBATROS, and the ongoing ATLANTIS, ALPHEUS, ARAMIS, ADRIFT trials.

Dr Montalescot is the Chairman of the ACTION study group, an Academic Research Organization based at Pitié Salpêtrière Hospital in Paris. He has served on several task force committees on antithrombotic drugs and acute coronary syndromes and is the current Chairman of the Stable Coronary Artery disease guidelines of the European Society of Cardiology.

Dr Montalescot has received several awards in his country including the J. Valade Prize from the Fondation de France and the J.Escalle award from the National Academy of Medicine. He is a member of several editorial boards and has published over 600 peer reviewed original articles in journals such as the NEJM, JAMA, Lancet. Internationally, Dr Montalescot has also been an invited speaker at plenary sessions of major congresses such as the European Society of Cardiology, the American College of Cardiology ,and the American Heart Association.

Prof. François Mach, MD, is a world-renowned cardiologist and scientist specialising in atherosclerosis, vascular biology, and preventive cardiology.

With an h-index >120, over 54,000 citations, and more than 850 publications, he is a leading authority in the field of cardiovascular disease development, progression, and prevention.

Following his medical and cardiology training at the University of Geneva and a formative postdoctoral fellowship in Prof. Peter Libby’s laboratory at Harvard Medical School, he established his foundational work on inflammation in atherogenesis.

Since 2006 he has been the head of the Cardiology Department at Geneva University Hospital, served as President of the Swiss Society of Cardiology (2012–2014) and continues to treat ambulatory/hospitalized patients regularly.

Prof. François Mach has been instrumental in developing and leading several major Swiss cardiovascular cohorts, including the SPUM-ACS cohort, which includes over 8,000 patients with acute coronary syndrome, and has established a robust infrastructure for clinical and translational research. His work spans from basic science to large-scale clinical trials and real-world evidence studies in lipidology and acute coronary syndromes.

A key contributor to international clinical guidelines, he co-chaired the 2019 ESC/EAS Guidelines for the management of dyslipidaemia and the 2021 ESC Guidelines on cardiovascular disease prevention. Recently, he co-chaired the 2025 ESC/EAS Focused Update on Dyslipidaemia Guidelines. His research is supported by numerous grants from the Swiss National Science Foundation (SNSF), the European Union, and various foundations.